

Joe Lombardo
Governor

Richard Whitley, MS
Director



**DEPARTMENT OF
HEALTH AND HUMAN SERVICES**
DIVISION OF HEALTH CARE FINANCING AND POLICY
Helping people. It's who we are and what we do.



Stacie Weeks,
JD MPH
Administrator

Silver State Scripts Board Meeting Minutes

Date of Meeting: Thursday, March 20, 2025, at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Scripts Board.

Agenda Item	Record	Notes																											
1. Closed Executive Session																													
a. Call to Order and Roll Call	<p>Chairperson Mark Decerbo called the meeting to order at 1:00 PM on March 20, 2025.</p> <p>Chairperson Decerbo took the roll.</p> <table><thead><tr><th></th><th>Present</th><th>Absent</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm. D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Present	Absent	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<p>DHCFP Staff Present were as follows:</p> <ul style="list-style-type: none">• Brown, Antonio, Chief of Pharmacy & DME• Flowers, Ellen, Social Services Program Specialist II• Cabrera, Donna, Program Officer I• Lithier, Gabriel, Senior Deputy Attorney General <p>NMAP Staff Present were as follows:</p> <ul style="list-style-type: none">• Johnson, Tory, Health Program Manager II
	Present	Absent																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Aditi Singh, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											

		<ul style="list-style-type: none"> • Cowan, Sarah, Health Program Specialist I <p>Prime Staff Present were as follows:</p> <ul style="list-style-type: none"> • Deoliveira, Brittany, Pharm.D., Clinical Account Manager • Mishra, Raj, Pharm.D., Clinical Account Manager • Martinez, Chris, Sr. Business Analyst • Perez, Melissa, Sr. Business Analyst
<p>b. Financial Review of Drug Classes with Proposed Changes</p>	<p>Chairperson Decerbo directed Dr. Brittany Deoliveira to proceed with the Financial Review of Drug classes with proposed changes up for review.</p> <p>Dr. Deoliveira reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session of the Silver States Scripts Board meeting.</p> <p>Dr. Deoliveira presented the financial review of the established drug classes being reviewed due to the release of new drugs, noting the products with proposed changes in PDL status.</p> <ul style="list-style-type: none"> • Self-Injectable Epinephrine • Short-Acting Beta Adrenergic (SABAs) <p>Dr. Deoliveira presented the financial review of the established drug classes with proposed changes, noting the products with proposed changes in PDL status.</p> <ul style="list-style-type: none"> • Antidepressants: Other • Sulfonylureas • Immunomodulators: Atopic Dermatitis 	

	<ul style="list-style-type: none"> • Opiate Agonists: Abuse Deterrents • Miscellaneous Analgesics: Mixed Acting Opioid Analgesics • Targeted Immunomodulator <p>Dr. Deoliveira presented the financial review of the new drug class, noting the product with proposed changes in PDL status.</p> <ul style="list-style-type: none"> • Non-Opioid Analgesics <p>Dr. Deoliveira presented the financial review of the NMAP established drug classes without proposed changes, noting the products with proposed changes in PDL status.</p> <ul style="list-style-type: none"> • Antiretrovirals: Entry Inhibitors; Integrase Inhibitors; Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTIs); Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs); Integrase Inhibitor/NRTI Combinations; NNRTI/NRTI Combinations; Protease Inhibitor (PI)/NRTI Combinations; CYP3A Inhibitors; Protease Inhibitors (PI); CYP3A4 Inhibitor/Protease Inhibitor Combinations; Integrase Inhibitor/NNRTI Combinations; Capsid Inhibitors; CD4-Directed Post Attachment Inhibitors; GP 120 Directed Attachment Inhibitors • Non-Narcotic Analgesic (Pain Relief) Medications • Antibiotics Medications • Anticoagulant Medications • Anticonvulsant Medications • Antidepressant/Antipsychotic/Hypnotic (Sleep Aid) Medications • Antidiarrheal Medications • Antiemetic (Anti-Nausea) Medications • Antifungal Medications • Antihistamine (Anti-Allergy) Medications • Antihypertensive (Anti-High Blood Pressure) Medications 	
--	---	--

	<ul style="list-style-type: none"> • Antivirals • Antivirals – Hepatitis • Antivirals – Direct Acting Antivirals (Hepatitis C Treatment) • Gastrointestinal Medications • Hematopoietic Medications • Hormone Replacement Therapy Medications: Androgens, Estrogens/Estrogenic Agents, Growth • Hormone Releasing Hormone Agents, Progestins • Hypoglycemic (High Blood Sugar) Medications • Inhalers: Asthma Prevention, Bronchodilators, Nasal Steroids, Oral Steroids • Lipid Lowering (Anti-Cholesterol) Medications • Osteoporosis (Bone) Medications • Pancreatic Enzyme Medications • PCP Prophylaxis Medications • Topical Medications 																												
2. Open Public Meeting																													
a. Call to Order and Roll Call	<p>Chairperson Decerbo called the meeting to order at 1:59 PM on March 20, 2025.</p> <p>A quorum was present.</p> <p>Chairperson Decerbo took the roll.</p> <table> <tr> <th></th><th>Present</th><th>Absent</th></tr> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Crumby, Pharm. D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </table>		Present	Absent	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<p>DHCFP Staff Present were as follows:</p> <ul style="list-style-type: none"> • Brown, Antonio, Chief of Pharmacy & DME • Flowers, Ellen, Social Services Program Specialist II • Cabrera, Donna, Program Officer I • Lithier, Gabriel, Senior Deputy Attorney General <p>NMAP Staff Present were as follows:</p>
	Present	Absent																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Aditi Singh, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											

		<ul style="list-style-type: none">Johnson, Tory, Health Program Manager IICowan, Sarah, Health Program Specialist I <p>Prime Staff Present were as follows:</p> <ul style="list-style-type: none">Deoliveira, Brittany, Pharm.D., Clinical Account ManagerMishra, Raj, Pharm.D., Clinical Account ManagerMartinez, Chris, Sr. Business AnalystPerez, Melissa, Sr. Business Analyst <p>The public attendee list is included as Attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list’s accuracy is not assured</p>												
b. Approval for previous Meeting Minutes from September 26, 2024.	<p>Chairperson Decerbo moved to approve the meeting minutes and Board Member Joseph Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											

	<ul style="list-style-type: none"> • Joseph Adashek, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 	
c. Public Comments	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>	
d. Status Update by DHCFP	<p>Chief of Pharmacy & DME, Antonio Brown, provided an announcement.</p> <ul style="list-style-type: none"> • Doctor Duncan sends her regards and apologies that she was unable to make it to today's meeting. • I just have a couple of brief announcements today as mentioning Governor Lombardi state of a state address, Nevada is considering splitting the Department of Health and Human Services into two entities, the Nevada Health Authority would oversee Nevada Medicaid, the state's health insurance exchange, and other health related programs. The split aims to improve efficiency and allow better coordination of health care services, increased bargaining power and lower health care costs. This plan is moving through the legislative process, and although the name is changing, this move will not affect the responsibilities and duties of this board. • The last announcement that I have for you is that we are still recruiting licensed pharmacists and physicians for our board. So if you're interested, please submit your CV at rxinfo@dhcfp.nv.gov and that is all I have for you guys today. 	
e. Status Update by NMAP	<p>Health Program Manager, Tory Johnson, provided an announcement.</p> <ul style="list-style-type: none"> • There is no update for NMAP today. 	
3. Clinical Presentations		

A. For Possible Action: Discussion and possible adoption of Self-Administered Epinephrine.																																						
i. <u>Public comment</u>	Telephonic and web comment was called for, and the phone lines were opened. Public comment was provided by Nicole Dellasantina, food allergy parent and advocate with three children.																																					
ii. Drug class review presentation by Prime.	Dr. Deoliveira discussed Neffy® nasal spray. She presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies. Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime, and Chairperson Decerbo seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			

iv.	Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended adding Neffy® nasal spray to the PDL as non-preferred. She also recommended removing Symjepi® and Adrenaclick® from PDL due to product discontinuation. Also recommended changing the drug class name from “Self-Injectable Epinephrine” to “Self-Administered Epinephrine”.																																					
v.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Vice Chairperson Kate Ward moved to approve the proposed changes as presented by Prime and Board Member Elizabeth Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
B.	For Possible Action: Discussion and possible adoption of Short-Acting Beta Adrenergics (SABAs)																																						
i.	<u>Public comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Dr. Christine Dube, Pharmacist with Medical Affairs employed by Astra Zeneca.</p>																																					

ii.	Drug class review presentation by Prime.	<p>Dr. Deoliveira discussed Airsupra HFA®. She presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.</p> <p>Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.</p>																																					
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
iv.	Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended adding Airsupra HFA® to the PDL as non-preferred. She also recommended removing Proair HFA® and Xopenex® from the PDL as these products are no longer on the market.</p>																																					
v.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Vice Chairperson Ward moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																									
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				

	<ul style="list-style-type: none"> • Joseph Adashek, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 	
C. For Possible Action: Discussion and possible adoption of Antidepressants: Other		
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Jay Mehta, Health Outcomes Liaison at Asxome Therapeutics.</p> <p>Public comment was provided by Linda Finch, Medical Accountant for Biogen.</p> <p>Public comment was provided by Robin with NAMI.</p>	
ii. Drug class review presentation by Prime.	<p>Dr. Deoliveira discussed Zurzuva[®], a new product within this drug class, Spravato and vilazodone. She presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.</p> <p>Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.</p>	
iii. Discussion by Board and action by Board to approve clinical/therapeutic	Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalez seconded the motion.	

equivalency of agents in class.	<p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
iv. Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended adding Spravato and vilazodone as preferred to the PDL and Zurzuvae® as non-preferred agents to the PDL. Dr. Deoliveira also recommended moving Forfivo XL and Pristiq branded products from preferred to non-preferred.</p>																																					
v. <u>Board Members Comments</u>	<ul style="list-style-type: none">• Dr. Khurana provided a comment• Dr. Adashek provided a comment• Dr. Ward Provided a comment																																					
vi. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Khurana moved to approve the proposed changes as presented by Prime with the change of having Zurzuvae® as preferred and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																					
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			

	<ul style="list-style-type: none">• Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>					
D. For Possible Action: Discussion and possible adoption of Sulfonylureas.						
i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.					
ii. Drug class review presentation by Prime.	Dr. Deoliveira recommended the board consider the class clinically and therapeutically equivalent.					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody>• Mark Decerbo, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Kate Ward, Pharm.D., Vice Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Joseph Adashek, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>• Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Sapandeep Khurana, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>• Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/></tbody></table>		Yes	No	Abst.	
	Yes	No	Abst.			

iv. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended adding glimepiride 3 mg as a non-preferred product on the PDL, and defining glimepiride preferred product with 1 mg, 2 mg and 4 mg. She also recommended removing Amaryl® and Glynase® from the PDL due to the products being discontinued.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Vice Chairperson Ward moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
E. For Possible Action: Discussion and possible adoption of Immunomodulators: Atopic Dermatitis.																																						
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Carla McSpadden, Pharmacist with Galderma.</p>																																					

	<p>Public comment was provided by Tyler Lincoln, Pharmacist with Arcutis.</p> <p>Public comment was provided by Jen Liang, Pharmacist in Health Outcomes, Liaison with Insight.</p> <p>Public comment was provided by Valley Ng, Pharmacist with the Field Medical Affairs at Leo Pharma.</p>																																					
ii. Drug class review presentation by Prime.	<p>Dr. Deoliveira presented Ebglyss®, Nemluvio® and Zoryve®. She also presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.</p> <p>Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.</p>																																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			

iv.	Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended moving pimecrolimus topical and Adbry® from non-preferred to preferred. She also recommended removing brand Elidel® from the PDL as this product has been discontinued. She also recommended adding Ebglyss®, Nemluvio® and Zoryve® as non-preferred.																																					
v.	Board Member Comments	Comment was provided by Board Member Ramirez.																																					
vi.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Ramirez moved to approve the proposed changes as presented by Prime and Vice Chairperson Ward seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
F.	For Possible Action: Discussion and possible adoption of Opiate Agonists: Abuse Deterrents.																																						
i.	<u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					

ii. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
iv. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended moving Oxycontin® from non-preferred to preferred. She also recommended removing Xtampza® ER as this product no longer participates in the Medicaid Drug Rebate Program.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Chairperson Decerbo moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																													
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			

	<ul style="list-style-type: none">• Kate Ward, Pharm.D., Vice Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Joseph Adashek, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>• Mark Crumby, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Sapandeep Khurana, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>• Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>• Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>																					
G. For Possible Action: Discussion and possible adoption of Miscellaneous Analgesics: Mixed Acting Opioid Analgesics.																						
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																					
ii. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																			
• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																			

	<ul style="list-style-type: none">Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>Sapandeep Khurana, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>Leana Ramirez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>																																					
iv. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommends removing Nucynta® and Nucynta® ER from the PDL as they no longer participate in the Medicaid Drug Rebate program. She also recommended removing Ultracet® and Seglentis® from the PDL as these products have been discontinued. She also recommended keeping tramadol IR 50 mg as the preferred product, and defining the 25 mg, 75 mg, and 100 mg IR tablets as non-preferred. She also recommended defining the tramadol soln as non-preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Chairperson Decerbo moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
H. For Possible Action: Discussion and possible adoption of Targeted Immunomodulator .																																						
i) <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were opened.																																					

	<p>Public comment was provided by Dr. Melinda Turkington, Medical Outcomes Liaison with UCB.</p> <p>Public comment was provided by Alexandra Kaiser, Pharmacist on the Field Health Economics and Outcomes Research Team at Bristol-Myers Squibb.</p> <p>Public comment was provided by Kristen Duffy, Pharmacist and Value Evidence Lead with Novartis Pharmaceuticals.</p>																																					
ii) Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																																					
iii) Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
iv) Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended moving the biosimilar products adalimumab-adbm and adalimumab-adaz from non-preferred to preferred, while keeping Humira preferred as well. She also recommends that the Quallent manufacturer of adalimumab-adbm be non-preferred, and all other manufacturers be preferred. Additionally,																																					

	she recommended moving Rinvoq (tablet and LQ solution) from non-preferred to preferred.																																					
v) Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Prime and Board Member Ramirez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
I. For Possible Action: Discussion and possible adoption of Non-Opioid Analgesics .																																						
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Barry Cole, Psychiatrist in Nevada.</p> <p>Public comment was provided by Chad Duck with the Health Economics Research Team at Vertex.</p>																																					

ii.	Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommends adding a new class of drugs to the PDL – the “non-opioid analgesics” due to the release of a new drug, Journavx®. Recommend to add Journavx® as preferred in this new class.																																					
iii.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
J.	For Possible Action: Discussion and possible adoption of NMAP: Established Drug Classes without Proposed Changes.																																						
i.	<u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Kenneth Berry, Pharmacist and Medical Science Director with Alchemy's.</p> <p>Public comment was provided by Dr. Jessica Jay with Endovirs Medical Outcomes and Value Liaison Team.</p>																																					

<p>ii. Established drug classes</p>	<ul style="list-style-type: none"> • Antiretrovirals: Entry Inhibitors; Integrase Inhibitors; Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTIs); Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs); Integrase Inhibitor/NRTI Combinations; NNRTI/NRTI Combinations; Protease Inhibitor (PI)/NRTI Combinations; CYP3A Inhibitors; Protease Inhibitors (PI); CYP3A4 Inhibitor/Protease Inhibitor Combinations; Integrase Inhibitor/NNRTI Combinations; Capsid Inhibitors; CD4-Directed Post Attachment Inhibitors; GP 120 Directed Attachment Inhibitors • Non-Narcotic Analgesic (Pain Relief) Medications • Antibiotics Medications • Anticoagulant Medications • Anticonvulsant Medications • Antidepressant/Antipsychotic/Hypnotic (Sleep Aid) Medications • Antidiarrheal Medications • Antiemetic (Anti-Nausea) Medications • Antifungal Medications • Antihistamine (Anti-Allergy) Medications • Antihypertensive (Anti-High Blood Pressure) Medications • Antivirals • Antivirals – Hepatitis • Antivirals – Direct Acting Antivirals (Hepatitis C Treatment) • Gastrointestinal Medications • Hematopoietic Medications • Hormone Replacement Therapy Medications: Androgens, Estrogens/Estrogenic Agents, Growth • Hormone Releasing Hormone Agents, Progestins • Hypoglycemic (High Blood Sugar) Medications • Inhalers: Asthma Prevention, Bronchodilators, Nasal Steroids, Oral Steroids • Lipid Lowering (Anti-Cholesterol) Medications • Osteoporosis (Bone) Medications • Pancreatic Enzyme Medications 	

	<ul style="list-style-type: none">• PCP Prophylaxis Medications• Topical Medications																																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Chairperson Decerbo motion to approve the established drug classes without changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Kate Ward, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Joseph Adashek, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Aditi Singh, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
K. Prime Reports	<p>New Drugs to Market and New Line Extensions</p> <ul style="list-style-type: none">• On The Horizon: Notable FDA Decisions Expected (1Q2025)• New infectious disease drug: clesrovimab• New cardiology drug: etripamil (Cardamyst)• New musculoskeletal drug: ataluren (Translarna)																																					
L. Closing Discussion																																						
vi. Public comments on any subject	Public comments were provided by Alvin Oung, Medical Science Liaison with Intracellular Therapies.																																					
vii. Date and location of the next meeting.	Date: June 12, 2025 Location: Courtyard by Marriott Las Vegas Convention Center 3275 Paradise Road, Las Vegas, NV, 89109																																					
viii. Adjournment	Chairperson Decerbo adjourned the meeting at 4:06 PM.																																					

Attachment A – Members of the Public in Attendance

Alexandra Kaiser	Fushimi Brent	Leslie Costalin	Sara Stolfus (Artia Solutions)	Lynda Finch - Biogen
Alvin Oung	Georgette Dzwilewski	Lisa Glick	Shadi A. Ahmed	Kenneth Garcia- Sanofi specialty
Amanda M Lattin	Hiten Patadia	Lisa Pulver [JANUS]	Shannon M Groppenbacher [SCGUS]	Stefanie Abraham - Taheda
Amy Hale [JANUS]	Hugh David Williams	Lucas Zhou	Steven Evans	Valerie Na - Leo Pharma
Angela Stewart	Jay Mehta	Marc Parker	Turkington Melinda	Carmen Hinton - EBSI
Angelo Alford	Jen Leung	Michael Pazirandeh	Tyler Lincoln	Mark Germann- Leo
Ann Marie O'Toole	Jessica Jay	Nick Boyer	Wahi R	Jeana Colabianchi - SMPA
Ayman Kafal	John Landis	Nicole Dellasantina	Robert Pearce -BMS	
Carla McSpadden	Joleen Walker	Nirmal Ghuman - J&J	Aaron Feyos- BMS	
Chris Johnson	JSDO (Jason Douglas)	Olivia Capperella	Lee Stout - Chiesi	
Christine Dube	Karen Ou	Paul Boothman	Ann Nelson - Vertex	
Connie Brooks	Kenneth Berry Kristin	Rianna White	Chad Duncan- Vertex	
Dan Allen	Duffey	Rich	Aaron Girvih - Biogen	
Deron Grothe	Lana Robards	Robin - NAMI Nv	Reiwa Rittman	
Eileen Zimmer	Juan D'Angelo	Ryan A Roa	Tina Hartmann - Arcutis	

Attachment B – Submitted Written Comment

[Public Comments](#)